Subscribe To

Price Alert Latest News Economic Calendar News

INKT / MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its independent fourth quarter and full year 2021 financial results and a business update before the market opens on Friday, March 18, 2022. Read More

Demo Live Account See Partner Details

Content Topics

Boombit

Bbt

Wa

Therapeutics

Report

Fourth

Quarter

Financial

Results

Business

Update

Stock

INKT

Posted: Mar 3 2022, 16:35

Author Name: GlobeNewsWire

INKT News

By GlobeNewsWire
September 27, 2023

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discove

By GlobeNewsWire
August 24, 2023

MiNK Therapeutics to Participate in September Investor Conferences

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery

By GlobeNewsWire
June 5, 2023

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery

By Seeking Alpha
May 14, 2023

MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Rela

By Zacks Investment Research
April 4, 2023

MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for MiNK Therapeutics, Inc. (INKT), indicating that the stock has found support

By Seeking Alpha
March 25, 2023

MiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Up

AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18.

By Seeking Alpha
March 21, 2023

MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2022 Results Conference Call March 21, 2023 8:30 AM ET Company Participants Zack Armen - Head of Investor Re

By GlobeNewsWire
February 16, 2023

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development,

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.